Evotec

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Webinar unpacks immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

#News

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Register for insight on ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

#News

#Biomarkers #Drug discovery #Evotec #Webinar

Last chance to register: Webinar unpacks PK/PD and QSP modeling

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

Cancer cells
#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Webinar explores applying ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

#News

Digital biomarkers
#Biomarkers #Drug discovery #Evotec #Webinar

Webinar connects PK/PD biomarkers with decision-making

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

Biomarkers concept
#Biomarkers #Drug discovery #Evotec #Webinar

Webinar: PK/PD and QSP modeling in translational biomarker development

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

New webinar: Applying ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

#News

#Biomarkers #Drug discovery #Evotec #Webinar

Webinar: From PK/PD and biomarkers to decision-making

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

#Biomarkers #Drug discovery #Evotec #Webinar

Webinar explores how modeling shapes clinical strategy

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

#Biomarkers #Drug discovery #Evotec #Webinar

From PK/PD and Biomarkers to decision-making: How modeling shapes clinical strategy

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars

T cells
#Collaboration #Evotec #Oncology #Plectonic Biotech #T cell engagers

Partners explore T cell engaging approaches for solid tumours

Evotec and Plectonic Biotech have announced a research collaboration to explore a novel immunotherapy approach for solid tumours.   The collaboration aims to address key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumours by combining Plectonic’s programmable LOGIBODY… Read More

#Business & Investment #Cancer Research #News

#Autoimmune disease #Collaboration #Evotec #Inflammatory diseases #Odyssey Therapeutics

Evotec joins Odyssey in autoimmune drug development

Evotec has entered a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments in autoimmune and inflammatory diseases.  Under the agreement, Odyssey will use Evotec’s data-driven discovery platform, screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across… Read More

#Business & Investment #News

Medical research
#Evotec #Inflammatory diseases #Preclinical development

Evotec nominates PDC for inflammatory skin disease programme 

Evotec has nominated its small molecule preclinical development candidate (PDC) as it advances a programme for inflammatory skin diseases.  The programme, developed as part of an alliance in medical dermatology with Almirall announced in 2022, will develop novel treatments for immune-mediated inflammatory skin diseases with high unmet… Read More

#News

Illustration of a virus
#Biomedical Advanced Research and Development Authority (BARDA) #Evotec #Monoclonal antibodies #Pandemic prevention

Just – Evotec Biologics enters $10m agreement with BARDA

Evotec’s subsidiary and CDMO, Just – Evotec Biologics, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimisation for a monoclonal antibody cocktail.  The therapy will target filovirus diseases, including Ebola virus (EBOV) and Sudan virus… Read More

#Business & Investment #News

#Clinical trial #Evotec #Kidney cancer

Evotec to receive $10m as kidney cancer trial launches 

Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway.  Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer.   The first-in-human study brings… Read More

#Business & Investment #News